3.65

4.70% -0.18

After Hours: 3.66 0.01 +0.27%

Cingulate Inc (CING)

Overview News Price History Financials Discussions Forecast

Cingulate Inc stock is traded at $3.65, with a volume of 66,605. It is down -4.70% in the last 24 hours and down -24.12% over the past month. Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Previous Close:

$3.83

Open:

$3.78

24h Volume:

66,605

Relative Volume:

0.02

Market Cap:

$11.11M

Revenue:

Net Income/Loss:

$-21.21M

P/E Ratio:

-2.1598

EPS:

-1.69

Net Cash Flow:

$-16.86M

1W Performance:

-16.86%

1M Performance:

-24.12%

6M Performance:

-68.47%

1Y Performance:

-96.36%

1-Day Range:

$3.64

$3.85

1-Week Range:

$3.64

$4.48

52-Week Range:

$1.8001

$152.40

Cingulate Inc Stock (CING) Company Profile

Name

Cingulate Inc

Sector

Healthcare (1181)

Industry

Biotechnology (671)

Phone

(913) 942-2300

Address

1901 W. 47TH PLACE, KANSAS CITY

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CING's Discussions on Twitter

Cingulate Inc Stock (CING) Latest News

Oct 08, 2024

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - The Manila Times

Oct 08, 2024

Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewswire

Oct 08, 2024

Oct 07, 2024

Cingulate secures funding to extend operations into Q2 2025 By Investing.com - Investing.com South Africa

Oct 07, 2024

SEC Form 424B3 filed by Cingulate Inc. - Quantisnow

Oct 07, 2024

Cingulate secures funding to extend operations into Q2 2025 - Investing.com India

Oct 07, 2024

Oct 05, 2024

Cingulate Inc. CEO faces domestic battery charge - Investing.com India

Oct 05, 2024

Oct 04, 2024

Cingulate Inc. CEO faces domestic battery charge By Investing.com - Investing.com South Africa

Oct 04, 2024

Sep 30, 2024

KC-area public company CEO faces charges for aggravated domestic battery - The Business Journals

Sep 30, 2024

Sep 28, 2024

Cingulate files to sell 1.5M shares of common stock for holders - MSN

Sep 28, 2024

Sep 24, 2024

Will Ciena's New 1.6 Tb/s Coherent Pluggable Solution Drive Top Line? - Zacks Investment Research

Sep 24, 2024

Concentrix Corp (CNXC) Q3 2024: Everything You Need to Know Ahea - GuruFocus.com

Sep 24, 2024

Cettire shares skyrocket - Finance News Network

Sep 24, 2024

Cettire gets auditor’s tick of approval, adding $247m to valuation - The Australian Financial Review

Sep 24, 2024

Citi upgrades Ciena, shares rise in pre-market trade By Investing.com - Investing.com Canada

Sep 23, 2024

9 Analysts Assess Ciena: What You Need To Know - Benzinga

Sep 23, 2024

Ciena Unveils 1.6 Tb/s Coherent Pluggable Solution for Hyperscale Cloud Providers' Capacity Surge - Marketscreener.com

Sep 23, 2024

Ciena's stock rises after Citi double upgrades to Buy (NYSE:CIEN) - Seeking Alpha

Sep 23, 2024

Citi sees growth potential for Ciena stock as inventory challenges ease - Investing.com Australia

Sep 23, 2024

Sep 21, 2024

Ciena Co. (NYSE:CIEN) Shares Sold by Thrivent Financial for Lutherans - Defense World

Sep 21, 2024

Sep 16, 2024

KC-area pharmaceutical company starts its last trial before seeking FDA approval - The Business Journals

Sep 16, 2024

CING’s Market Whiplash: -94.12% YTD Decline, 192.68% Rise in 30 Days - The InvestChronicle

Sep 16, 2024